About

ImmunoBiochem develops novel degrader-antibody conjugate (DAC) therapeutics for precision immunology, utilizing computational tools and AI to engineer non-cytotoxic payloads with favorable biophysical properties, targeting disease pathways inaccessible to other modalities. Their lead molecule, IMB216P, targets CD127/IL7RA with a JAK1/TYK2 dual-degrader payload, offering immune system reset for autoimmune disorders across conditions like IBD, PsO, PsA, SLE, T1D, RA, JIA, SpA, IPF, SjD, GvHD, and MS, without broad immunosuppression.

Products & services in North York

Keywords

engineering firm

Similar companies nearby